We conclude that monoclonal antibodies directed against VEGF are mainly applied as adjunctive treatment to reduce macular exudation; in VHL patients with advanced juxtapapillary or peripheral retinal hemangioblastomas, which are ineligible for conventional treatment.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}